Adial Pharmaceuticals (ADIL) Expected to Announce Earnings on Wednesday

Adial Pharmaceuticals (NASDAQ:ADIL) is projected to release its results before the market opens on Wednesday, November 12th. Analysts expect Adial Pharmaceuticals to post earnings of ($0.09) per share for the quarter.

Adial Pharmaceuticals (NASDAQ:ADIL) last released its earnings results on Wednesday, August 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.04. On average, analysts expect Adial Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Adial Pharmaceuticals Stock Performance

ADIL opened at $0.33 on Wednesday. The firm has a market cap of $7.10 million, a P/E ratio of -0.31 and a beta of 1.32. Adial Pharmaceuticals has a 52-week low of $0.22 and a 52-week high of $1.30. The business’s fifty day moving average is $0.36 and its 200-day moving average is $0.45.

Analyst Ratings Changes

Several brokerages have commented on ADIL. Weiss Ratings reissued a “sell (e+)” rating on shares of Adial Pharmaceuticals in a research note on Wednesday, October 8th. Zacks Research downgraded Adial Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 20th. Maxim Group raised Adial Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.50 target price for the company in a research note on Tuesday, September 30th. Finally, Wall Street Zen raised Adial Pharmaceuticals to a “sell” rating in a research note on Saturday, July 26th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $4.75.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.